| Market Cap | $1.12B+14.3% |
| Revenue (ttm) | $796.53M |
| Net Income | $164.71M |
| EPS | $23.11 |
| Shares Out | 6.86M |
| PE Ratio | 7.04 |
| Forward PE | 8.00 |
| Dividend | n/a |
| Ex-Dividend Date | Nov 30, 2026 |
| Volume | 157,523 |
| Open | $157.61 |
| Previous Close | $162.10 |
| Day's Range | $155.04 - $165.14 |
| 52-Week Range | $83.99 - $226.16 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | $313.67(+92.86%) |
| Earnings Date | Nov 5, 2026 |
About NUTX
Nutex Health Inc. operates as a healthcare services and operations company in the United States. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. Nutex Health Inc. was founded in 2011 and is headquartered in Houston, Texas.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating NUTX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 30, 2026Ex-dividend date
$NUTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NUTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NUTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NUTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NUTX Revenue by Segment
| Segment Information | $217.61M | 64.33% |
| Payroll | $48.41M | 14.31% |
| Contract services | $43.69M | 12.92% |
| Corporate and other costs | $24.43M | 7.22% |
| Medical supplies | $4.13M | 1.22% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New NUTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NUTX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from NUTX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strong Q3 earnings growth (159% net income jump), dividend declaration, analyst upgrade to $357 target, and reimbursement/hospital growth drive positive momentum.
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 19Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| ECML | Euclidean Fundamental Value ETF | 1.62% |
| ABLS | Abacus FCF Small Cap Leaders ETF | 1.52% |
| XHS | State Street SPDR S&P Health Care Services ETF | 1.41% |
| VAMO | Cambria Value and Momentum ETF | 1.27% |
| RNIN | EA Series Trust - Bushido Capital US SMID Cap Equity ETF | 0.98% |
| SFLO | VictoryShares Small Cap Free Cash Flow ETF | 0.79% |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 0.53% |
| IVSS | Applied Finance IVS US SMID ETF | 0.38% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.32% |
| AESG | Harbor AlphaEdge Small Cap Growth ETF | 0.31% |
| JPSE | JPMorgan Diversified Return U.S. Small Cap Equity ETF | 0.31% |
| FYX | First Trust Small Cap Core AlphaDEX Fund | 0.25% |
Weight is the stock’s share of each fund’s holdings.
